🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 16 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/09/2010 22,35 22,55 22,04 22,35 -0,04% 2,28% 646.400
29/09/2010 22,14 22,60 22,07 22,36 +0,36% 2,39% 490.800
28/09/2010 22,24 22,53 21,89 22,28 -0,13% 2,88% 1.629.300
27/09/2010 22,37 22,48 22,20 22,31 -0,40% 1,25% 975.000
24/09/2010 22,69 22,69 22,31 22,40 +0,22% 1,67% 986.200
23/09/2010 22,54 22,79 22,30 22,35 -1,54% 2,17% 799.800
22/09/2010 23,12 23,28 22,61 22,70 -1,69% 2,90% 847.000
21/09/2010 22,99 23,26 22,88 23,09 +0,17% 1,65% 666.500
20/09/2010 22,90 23,25 22,84 23,05 +0,26% 1,79% 371.600
17/09/2010 22,78 23,11 22,66 22,99 +1,32% 1,98% 496.900
16/09/2010 22,48 23,10 22,37 22,69 +0,49% 3,25% 1.761.600
15/09/2010 22,26 22,59 21,96 22,58 +1,21% 2,83% 793.300
14/09/2010 22,56 22,73 22,21 22,31 -1,72% 2,30% 1.239.300
13/09/2010 22,79 22,95 22,64 22,70 +0,00% 1,36% 463.700
10/09/2010 22,70 22,88 22,38 22,70 +0,35% 2,20% 988.100
09/09/2010 22,75 22,79 22,38 22,62 +0,62% 1,80% 597.700
08/09/2010 21,70 22,48 21,54 22,48 +4,17% 4,33% 793.900
07/09/2010 21,48 21,65 21,36 21,58 +0,37% 1,35% 471.100
03/09/2010 21,41 21,75 21,41 21,50 +0,99% 1,59% 411.800
02/09/2010 20,89 21,32 20,81 21,29 +1,72% 2,44% 739.600
01/09/2010 21,00 21,06 20,63 20,93 +3,15% 2,05% 890.200
31/08/2010 20,35 20,60 20,13 20,29 -0,98% 2,31% 1.018.900
30/08/2010 20,83 20,99 20,45 20,49 -1,35% 2,59% 417.900
27/08/2010 20,47 20,79 20,06 20,77 +2,72% 3,57% 458.300
26/08/2010 20,52 20,61 20,15 20,22 -0,83% 2,24% 846.300
25/08/2010 19,96 20,45 19,89 20,39 +1,95% 2,81% 419.800
24/08/2010 20,15 20,20 19,95 20,00 -1,48% 1,24% 661.000
23/08/2010 20,78 21,00 20,28 20,30 -1,55% 3,46% 406.200
20/08/2010 20,65 20,68 20,50 20,62 +0,00% 0,87% 802.700
19/08/2010 20,45 20,68 20,36 20,62 +0,34% 1,56% 626.800